Results 51 to 60 of about 72,871 (224)

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registryResearch in context

EClinicalMedicine, 2023
Summary: Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/
Jon Salmanton-García, Francesco Marchesi, Maria Gomes da Silva, Francesca Farina, Julio Dávila-Valls, Yavuz M. Bilgin, Andreas Glenthøj, Iker Falces-Romero, Jaap Van Doesum, Jorge Labrador, Caterina Buquicchio, Shaimaa El-Ashwah, Verena Petzer, Jens Van Praet, Martin Schönlein, Michelina Dargenio, Gustavo-Adolfo Méndez, Stef Meers, Federico Itri, Antonio Giordano, László Imre Pinczés, Ildefonso Espigado, Zlate Stojanoski, Alberto López-García, Lucia Prezioso, Ozren Jaksic, Antonio Vena, Nicola S. Fracchiolla, Tomás José González-López, Natasa Colović, Mario Delia, Barbora Weinbergerová, Monia Marchetti, Joyce Marques de Almeida, Olimpia Finizio, Caroline Besson, Monika M. Biernat, Toni Valković, Tobias Lahmer, Annarosa Cuccaro, Irati Ormazabal-Vélez, Josip Batinić, Noemí Fernández, Nick De Jonge, Carlo Tascini, Amalia N. Anastasopoulou, Rémy Duléry, Maria Ilaria Del Principe, Gaëtan Plantefeve, Mario Virgilio Papa, Marcio Nucci, Moraima Jiménez, Avinash Aujayeb, José-Ángel Hernández-Rivas, Maria Merelli, Chiara Cattaneo, Ola Blennow, Anna Nordlander, Alba Cabirta, Gina Varricchio, Maria Vittoria Sacchi, Raul Cordoba, Elena Arellano, Stefanie K. Gräfe, Dominik Wolf, Ziad Emarah, Emanuele Ammatuna, Ditte Stampe Hersby, Sonia Martín-Pérez, Raquel Nunes Rodrigues, Laman Rahimli, Livio Pagano, Oliver A. Cornely, Klára Piukovics, Cristina De Ramón, François Danion, Ayel Yahya, Anna Guidetti, Carolina Garcia-Vidal, Uluhan Sili, Joseph Meletiadis, Elizabeth De Kort, Luisa Verga, Laura Serrano, Nurettin Erben, Roberta Di Blasi, Athanasios Tragiannidis, José-María Ribera-Santa Susana, Hans-Beier Ommen, Alessandro Busca, Nicola Coppola, Rui Bergantim, Giulia Dragonetti, Marianna Criscuolo, Luana Fianchi, Matteo Bonanni, Andrés Soto-Silva, Malgorzata Mikulska, Marina Machado, Chi Shan Kho, Nazia Hassan, Eleni Gavriilaki, Gregorio Cordini, Louis Yi Ann Chi, Matthias Eggerer, Martin Hoenigl, Juergen Prattes, María-Josefa Jiménez-Lorenzo, Sofia Zompi, Giovanni Paolo Maria Zambrotta, Gökçe Melis Çolak, Nicole García-Poutón, Tommaso Francesco Aiello, Romane Prin, Maria Stamouli, Michail Samarkos   +115 more
doaj   +1 more source

Contraindicated drug–drug interactions and associated adverse drug reactions in an observational cohort study of 4543 paediatric hospitalized patients

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval, Sylvain Goutelle, Inesse Boussaha, Xavier Dode, Yanis Mimouni, Kim An Nguyen, Behrouz Kassai   +6 more
wiley   +1 more source

The interaction between nirmatrelvir/ritonavir and sirolimus: a case report of a kidney recipient with renal insufficiency and COVID-19

Journal of International Medical Research
Nirmatrelvir/ritonavir is a novel drug combination authorized by the US Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19).
Yinhua Gong, Dan Shen, Jinfang Shi, Ye Jiang, Jie Gao   +4 more
doaj   +1 more source

Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series

Clinical Case Reports, 2020
Key Clinical Message The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that
Hayato Koba, Taro Yoneda, Tomoya Kaneda, Tsukasa Ueda, Hideharu Kimura, Kazuo Kasahara   +5 more
doaj   +1 more source

Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: A randomized clinical trial [PDF]

, 2015
This article has been accepted for publication in Clinical Infectious Diseases ©2014 The Authors .Published by Oxford University Press on Clinical Infectious Disease 60.5. DOI: 10.1093/cid/ciu898Background.
Aguilar, A., Antela, A., Arcaina, P., Arnaiz, J. A., Arnaiz, Juan A., Arribas, J. R., Asensi, V., Barrera, G., Beleta, H., Beleta, Helena, Bernardino, J. I., Bernardino, Jose I., Blanco, J. R., Cairó, M., Carton, Jose A., Cartón, J. A., Castro, J. M., Crespo, M., Curran, A., Curran, Adrià, Dalmau, D., Deulofeu, Ramon, Domingo, P., Domingo, Pere, Dronda, F., Ferrer, E., Ferrer, Elena, Garcia, D., Garcia, David, Gatell, J. M., Gatell, Jose M., Giner, L., Gonzalez-Cordon, Ana, González-Cordón, A., Gutierrez, Felix, Gutierrez, M., Gutiérrez, F., Lamas, A., Losada, E., Martinez, Esteban, Martí-Belda, P., Martínez, E., Masiá, M., Mateo, M. G., Moya, S., Murillas, J., Murillas, Javier, Negredo, E., Negredo, Eugenia, Padilla, S., Pampliega, M., Pejenaute, Andrea, Pejenaute, Andrea, Peraire, J., Peraire, Joaquim, Pich, J., Pich, Judit, Podzamczer, Daniel, Podzamczer, Daniel, Portilla, J., Portilla, Joaquin, Prieto, A., Puig, J., Pérez, I., Pérez, Ignacio, Ramos, J. R., Ramos, Nuria, Ramos, Nuria, Ribera, Esteban, Ribera, Esteban, Robledano, C., Rozas, N., Santos, I., Santos, Ignacio, Sanz, J., Saumoy, M., Vargas, M., Velli, P., Vidal, F., Viladés, C.   +79 more
core   +2 more sources

Population Pharmacokinetics of Ticagrelor during Veno‐Arterial ECMO in Acute Coronary Syndrome: Model‐Informed Dosing Simulations

Clinical Pharmacology &Therapeutics, EarlyView.
Although patients with acute coronary syndrome supported by veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR ...
Soyoung Kang, Kyoung Lok Min, Seungwon Yang, Jongsung Hahn, Dasohm Kim, Byung Hak Jin, Soon Uk Chae, Soo Kyung Bae, Jin Wi, Min Jung Chang   +9 more
wiley   +1 more source

Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients

Viruses
(1) Background: Geriatric patients are at high risk of complications of Coronavirus disease-2019 (COVID-19) and are good candidates for antiviral drugs.
Nadia Exquis, Benjamin Dionisi, Caroline Flora Samer, Victoria Rollason, François Curtin, Dina Zekry, Christophe Graf, Virgnie Prendki, Kuntheavy Ing Lorenzini   +8 more
doaj   +1 more source

Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration [PDF]

, 2011
Article approval pendingWith expanding pediatric antiretroviral therapy (ART) access, children will begin to experience treatment failure and require second-line therapy. We evaluated the probability and determinants of virologic failure and switching in
Boulle, Andrew, Davies, Mary-Ann, Egger, Matthias, Eley, Brian, Giddy, Janet, Keiser, Olivia, Moultrie, Harry, Rabie, Helena, Technau, Karl, Van Cutsem, Gilles, Wood, Robin   +10 more
core   +2 more sources

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring [PDF]

, 2018
Objectives: The resistance profiles of patients receiving long-term ART in sub-Saharan Africa have been poorly described. This study obtained a sensitive assessment of the resistance patterns associated with long-term tenofovir-based ART in a ...
Appiah, Lambert T, Beloukas, Apostolos, Chadwick, David, Geretti, Anna Maria, Phillips, Richard O, Ruggiero, Alessandra, Sarfo, Fred S, Smith, Colette, Stockdale, Alexander J, Villa, Giovanni   +9 more
core   +3 more sources